Abstract Details

Title Determinants of HIV-Associated Neuropathic Pain Using a Novel Instrument

Topic Neuromuscular and Clinical Neurophysiology (EMG)

Presentation(s) P3 - Poster Session 3 (5:30 PM-6:30 PM)

Poster/Presentation
Number 12-020

Objective

To determine the determinants of neuropathic pain among HIV-positive individuals using a new diagnostic measure - the HANP-Q.

Background Neuropathic pain is present in about 40% of HIV-positive persons and significantly impairs their quality of life. The HIV-AIDS neuropathic pain questionnaire (HANP-Q) is a newly developed instrument for measuring neuropathic pain in persons with HIV/AIDS.

Design/Methods Ethical approval was obtained. It was a descriptive cross-sectional study using a convenience sampling technique. 100 HIV-positive adults were recruited post-validation of the questionnaire development. The HANP-Q was administered to all the participants with a score of ≥ 2 as the criteria for diagnosing neuropathic pain. A standard proforma was used to collect information on age, anthropometric indices, and disease-related variables. Determinants of neuropathic pain were dichotomized into categorical variables. Data were analyzed using descriptive and inferential statistics.

Results There 30 males and 70 females giving a male-female ratio of 1: 2.3. The ages of the patients ranged from 22.0 - 66.0 years with a mean of 39.2 ± 9.6 years. Thirty-four (34.0%) were drug-naïve. The mean duration of HIV was 49.6 ± 47.5 months. The mean duration HIV treatment was 43.8 ± 45.8 months. CD4+ cell counts ranged from 7.0-1464.0 cells/uL with mean of 379.4 ± 277.3 cells/uL. The viral load (VL) ranged from 0.0-1169750.0 copies/ml. Eight (8.0%) of the individuals were diagnosed of neuropathic pain using the HANP-Q. HIV duration (p = 0.036) was associated with neuropathic pain from univariate analysis. None of the variables was predictive of neuropathic pain from logistic regression analysis.

Conclusions Duration of HIV infection was the only determinant for neuropathic pain in this study from univariate analysis. This is in keeping with findings from several studies which have supported the duration of HIV diagnosis as a risk factor for developing neurological complications.

Authors/Disclosures
Alagoma M. Iyagba, MD PRESENTER	No disclosure on file
Mayowa Owolabi, MD, FAAN (Neurology Unit, Dept of Med, UCH)	Dr. Owolabi has nothing to disclose.
Adesola Ogunniyi, MD	Dr. Ogunniyi has nothing to disclose.

��ɫ��

��ɫ��